BIO sues to block Medicare drug pricing pilot tied to foreign benchmarks

The Biotechnology Innovation Organization (BIO) has joined litigation against a Medicare pilot that would tie US drug prices to those in peer countries, testing Trump's most-favored-nation approach. The pilot's impact is likely limited, but the legal challenge signals industry resistance to international reference pricing.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works